Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
Fate Therapeutics
Merck Sharp & Dohme LLC
BioNTech SE
Eisai Inc.
Eisai Inc.
M.D. Anderson Cancer Center
GlaxoSmithKline
AstraZeneca
Ohio State University Comprehensive Cancer Center
University of Oklahoma
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Gilead Sciences
Faeth Therapeutics
AstraZeneca
GlaxoSmithKline
Washington University School of Medicine
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Bio-Thera Solutions
Incyte Corporation
Leap Therapeutics, Inc.
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
GlaxoSmithKline
Seoul National University Hospital
University of Maryland, Baltimore
Yonsei University
Merck Sharp & Dohme LLC
Mario Negri Institute for Pharmacological Research
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Huabo Biopharm Co., Ltd.
Hutchmed
Washington University School of Medicine
Deciphera Pharmaceuticals, LLC
Peking Union Medical College Hospital
Leiden University Medical Center
Merck Sharp & Dohme LLC
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
NETRIS Pharma